Indian innovation takes center stage as IIT Roorkee unveils a state-of-the-art platform for antibody discovery. Tailored for battling cancer, infections, autoimmunity, and new pathogens, it delivers high-stability, high-affinity antibodies with unprecedented speed.
Powered by a comprehensive single-domain antibody library, the system ensures diversity and potency. Nanobodies’ natural advantages—compact size and durability—make them perfect for demanding therapeutic roles.
By compressing timelines, it revolutionizes healthcare agility, especially in crises. This addresses longstanding bottlenecks, making advanced tools viable even in urgent scenarios.
From the Department of Biosciences and Bioengineering, Prof. Rajesh Kumar shared: ‘Our high-diversity platform strengthens swift disease interventions and equitable access to diagnostics and therapies.’
It embodies Atmanirbhar Bharat by fostering self-reliance in biotech, generating IP, and streamlining research translation. Essential for developing economies, it tackles access barriers head-on.
Prof. K.K. Pant, the institute’s Director, celebrated: ‘This exemplifies how research, intent, and partnerships conquer key challenges.’
A new MoU with Imgenex India boosts collaborative efforts in antibody tech, advanced biologics, diagnostics, therapeutics, and bioprocesses, enhancing national capacities.
In summary, IIT Roorkee’s platform is more than tech—it’s a pillar of health sovereignty, readying India for tomorrow’s threats with cutting-edge, indigenous solutions.